Matthew W. Foehr
2017 - Ligand Pharmaceuticals
In 2017, Matthew W. Foehr earned a total compensation of $3.5M as President and Chief Operating Officer at Ligand Pharmaceuticals, a 22% increase compared to previous year.
Compensation breakdown
| Bonus | $30,000 |
|---|---|
| Non-Equity Incentive Plan | $265,256 |
| Option Awards | $1,280,493 |
| Salary | $442,094 |
| Stock Awards | $1,387,985 |
| Other | $52,675 |
| Total | $3,458,503 |
Foehr received $1.4M in stock awards, accounting for 40% of the total pay in 2017.
Foehr also received $30K in bonus, $265.3K in non-equity incentive plan, $1.3M in option awards, $442.1K in salary and $52.7K in other compensation.
Rankings
In 2017, Matthew W. Foehr's compensation ranked 3,056th out of 14,666 executives tracked by ExecPay. In other words, Foehr earned more than 79.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,056 out of 14,666 | 79th |
Division Manufacturing | 1,052 out of 5,768 | 82nd |
Major group Chemicals And Allied Products | 284 out of 2,074 | 86th |
Industry group Drugs | 216 out of 1,730 | 88th |
Industry Pharmaceutical Preparations | 171 out of 1,329 | 87th |
Source: SEC filing on April 30, 2018.
Foehr's colleagues
We found three more compensation records of executives who worked with Matthew W. Foehr at Ligand Pharmaceuticals in 2017.